You are subscribed to one of the following page update alerts:
Vaccine Code Set Update Publication Date: July 30, 2021
CORRECTED RELEASE NOTES August 5, 2021
The individual filenames included in this distribution contain the publication date (20210730)
CORRECTION: Table 4 “MVX Changes for Existing NDCs” in the release notes sent August 2, 2021 contained NDC code transcription errors. The table has been replaced in this version of the release notes. The code set file data is correct and has not been changed.
Release notes are designed as a guide to highlight changes that have been made to the vaccine codes since the last publication. They should not be used as the primary source of code information. The vaccine code files themselves should be utilized.
Release Notes: This release includes updates for all vaccine codes including Vaccine Information Statement (VIS) codes and maps.
General Note regarding this release: Codes with “Last Update” dates after May 17, 2021 and before July 30, 2021 reflect the changes and additions in this release. This is a large release and includes the following code set updates:
- Vaccine Code Set Updates Not Related to COVID-19
- New and retired codes for seasonal influenza vaccines
- Other vaccine code additions and changes
- COVID-19 Related Code Updates
- Non-U.S. COVID-19 vaccine code additions and updates
- Other COVID-19 Related Code Changes
Vaccine Code Set Updates
1. Vaccine Code Updates Not Related to COVID-19
- New 2021/2022 Seasonal Influenza Vaccines
Vaccine codes for the 2021/2022 seasonal influenza vaccines have been added as shown in Table 1 below. Also updated are the two website tables “2021/2022 Seasonal Influenza Codes and Crosswalk” and “Southern Hemisphere 2021 Seasonal Influenza Codes.” The two tables are available on the CDC website table using the following link: https://www.cdc.gov/vaccines/programs/iis/code-sets.html
Table 1: Seasonal Influenza NDCs Added for the 2021/2022 Influenza Season
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 | Presentation | CVX Code | MVX Code |
|---|
Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 19515-0818-52 | 19515-0818-41 | SYRINGE, .5 mL | 150 | IDB |
|---|
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0421-10 | 49281-0421-58 | VIAL, .5 mL, SINGLE-DOSE | 150 | PMC |
|---|
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0421-50 | 49281-0421-88 | SYRINGE, .5 mL | 150 | PMC |
|---|
FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 58160-0887-52 | 58160-0887-41 | SYRINGE, .5 mL | 150 | SKB |
|---|
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0635-15 | 49281-0635-78 | VIAL, 5 mL, MULTI-DOSE | 158 | PMC |
|---|
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0521-25 | 49281-0521-00 | SYRINGE, .25 mL | 161 | PMC |
|---|
FLUCELVAX QUADRIVALENT | Seqirus Inc. | 70461-0321-03 | 70461-0321-04 | SYRINGE, .5 mL | 171 | SEQ |
|---|
Flublok Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 49281-0721-10 | 49281-0721-88 | SYRINGE, .5 mL | 185 | PMC |
|---|
FLUCELVAX QUADRIVALENT | Seqirus Inc. | 70461-0421-10 | 70461-0421-11 | VIAL, 5 mL, MULTI-DOSE | 186 | SEQ |
|---|
FLUZONE High-Dose Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 49281-0121-65 | 49281-0121-88 | SYRINGE, .7 mL | 197 | PMC |
|---|
FLUAD QUADRIVALENT | Seqirus, Inc. | 70461-0121-03 | 70461-0121-04 | SYRINGE, .5 mL | 205 | SEQ |
|---|
Waiting on the following information (not included in this release):
- FLUAD (trivalent) NDC codes have not been provided as of this release for the 2021/2022 season
- Flumist NDC codes have not been provided as of this release for the 2021/2022 season
- Afluria NDC codes have not been provided as of this release for the 2021/2022 season
- Retired 2020/2021 Seasonal Influenza NDCs
Table 2 below identifies the influenza vaccine NDC codes that have been retired for the 2020/2021 season.
Table 2: 2020/2021 Seasonal Influenza NDCs Retired
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 |
|---|
FLUAD QUADRIVALENT | Seqirus, Inc. | 70461-0120-03 | 70461-0120-04 |
|---|
FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 58160-0885-52 | 58160-0885-41 |
|---|
Flublok Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 49281-0720-10 | 49281-0720-88 |
|---|
FLUCELVAX QUADRIVALENT | Seqirus Inc. | 70461-0420-10 | 70461-0420-11 |
|---|
FLUCELVAX QUADRIVALENT | Seqirus Inc. | 70461-0320-03 | 70461-0320-04 |
|---|
Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 19515-0816-52 | 19515-0816-41 |
|---|
FLUZONE High-Dose Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 49281-0120-65 | 49281-0120-88 |
|---|
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0420-50 | 49281-0420-88 |
|---|
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0420-10 | 49281-0420-58 |
|---|
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0520-25 | 49281-0520-00 |
|---|
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0633-15 | 49281-0633-78 |
|---|
- Other Vaccine Code Additions and Changes
Non-Influenza Vaccine NDCs Added: The following new Vaccine NDCs have been added for RabAvert.
Table 3: New Vaccine NDCs
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 | Presentation | CVX Code | MVX Code |
|---|
RabAvert | Bavarian Nordic A/S | 50632-0010-01 | 50632-0013-01 | VIAL, SINGLE-DOSE, 1 mL | 176 | SKB |
|---|
MVX Code Changes: The following NDCs have had a change to their associated MVX Code (new MVX Codes shown)
Table 4: MVX Changes for Existing NDCs
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 | MVX Code |
|---|
Vaxelis | MSP Vaccine Company | 63361-0243-10 | 63361-0243-58 | MSP |
|---|
Vaxelis | MSP Vaccine Company | 63361-0243-15 | 63361-0243-88 | MSP |
|---|
BCG VACCINE | Merck Sharp & Dohme Corp. | 00052-0603-02 | 00052-0603-01 | MSD |
|---|
MVX Code Changes: The following additional manufacturer MVX code additions and updates have been made.
- New Manufacturer MVX Code Added
MSP | MSP Vaccine Company - (partnership Merck and Sanofi Pasteur) | U.S. Based - Joint manufacturing partnership, initial vaccine Vaxelis 10/2020 |
|---|
OTC | Organon Teknika Corporation | Subsidiary of Merck. Sold by Merck 6/8/2021.
Effective June 2021 Merck is now labeler for the TICE BCG product. |
|---|
- Manufacturer Name Change for Existing MVX Code
PAX | Emergent Travel Health, Inc (Formerly PaxVax) | Emergent Biosolutions acquired PaxVax 8/2021,
U.S. Vaccines starting to label under Emergent Travel Health Ins. |
|---|
2. COVID-19 Related Code Updates
- Non-U.S. COVID-19 Vaccine Code Additions and Updates
The CDC has added and updated CVX codes, MVX and Product Tradename codes to support documentation of non-U.S. COVID-19 vaccine administration history records.
During the pandemic, multiple COVID-19 vaccines have been developed and are being administered internationally.
In this release, COVID-19 Non-U.S. CVX codes, associated MVX and Product Codes have been added or updated in the main code set data files to provide additional codes for use in documenting historic non-U.S. administration. A new table located on the CDC website, “COVID-19 Related Codes,” specifically identifies all CVX codes that might be used for non-U.S. vaccinations. This website table, “Preview Posting of COVID-19 Vaccine Codes and Crosswalks to be used for non-U.S. vaccine administration,” provides all the new/updated CVX codes in one place including associated code notes that can provide guidance for documenting COVID-19 vaccines administered outside of U.S. jurisdiction. The on-line table and downloadable files are available on this link: https://www.cdc.gov/vaccines/programs/iis/COVID-19-related-codes.html#codes
Additional Notes: The list of vaccines not authorized by the WHO may be incomplete. The list of vaccines indicated to be WHO-authorized will be updated periodically as the CDC monitors WHO-published information. All the COVID-19 related CVX codes are associated to the Vaccine Group "COVID-19."
Updates and additions to the CVX codes for COVID-19 include:
- Six existing COVID-19 CVX codes have had the Notes field updated to provide non-U.S. tradenames and use guidance, one code has changed status (see AstraZeneca below)
- Twelve new COVID-19 non-U.S. CVX codes have been added to reflect vaccines known to be available in the global market. Two of these are indicated as WHO-authorized vaccines which will be counted toward U.S. immunity. For the two WHO-authorized vaccines, new MVX codes and Product table codes have been added and associated to those CVX codes.
Two MVX codes have been added for the WHO authorized COVID-19 non-US vaccines:
MVX Code | Manufacturer | Notes | Status |
|---|
SPH | Sinopharm-Biotech | Non-US COVID-19 Vaccine Manufacturer - WHO Authorized | Active |
|---|
SNV | Sinovac | Non-US COVID-19 Vaccine Manufacturer - WHO Authorized (Sinovac, CoronaVac) | Active |
|---|
Five CDC Product Tradename table records have been updated or added to incorporate international tradenames that may appear on non-US vaccine record for U.S. and WHO authorized vaccines:
Product Tradename(s) | CVX Code | MVX Code |
|---|
AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD) | 210 | ASZ |
|---|
Coronavac (Sinovac) COVID-19 Vaccine | 511 | SNV |
|---|
Moderna COVID-19 Vaccine (non-US Spikevax) | 207 | MOD |
|---|
Sinopharm (BIBP) COVID-19 Vaccine | 510 | SPH |
|---|
Pfizer-BioNTech COVID-19 Vaccine (Non-US COMIRNATY) | 208 | PFR |
|---|
- Other COVID-19 Related Code Changes
AstraZeneca COVID-19 vaccine NDC codes have been temporarily inactivated pending U.S. regulatory submission and FDA review. The end dates for Unit of Sale NDC11 00310-1222-15 and Unit of Use NDC11 00310-1222-10 have been set to 7/31/2021. The following changes have also been made.
- CVX Code 210 for AstraZeneca COVID-19 vaccine; status has been changed to “non-US” from “active” to reflect that this vaccine is currently only available outside the U.S.
- The VIS Edition Status for the EUA Recipient Fact Sheet has been changed to “Historic” from “Current”
